GLP3-RT "Retatrutide" (20mg)

Variant specifications

Selected product: GLP3-RT "Retatrutide" (20mg)

Declared strength: 20mg total for this specific listing. Its SKU, price, inventory, and lot documentation are maintained separately from the other strength options.

Other available strengths: GLP3-RT "Retatrutide" (10mg) · GLP3-RT "Retatrutide" (15mg) · GLP3-RT "Retatrutide"(30mg) · GLP3-RT "Retatrutide"(60mg)

The research overview below describes the shared compound or blend. Strength-specific purchasing and documentation details apply only to the selected listing above.

Retatrutide is an investigational once-weekly injectable "triple-agonist" weight-loss and metabolic drug developed by Eli Lilly that targets GLP-1, GIP, and glucagon receptors. Eli Lilly announced plans to file for U.S. FDA approval in the first quarter of 2027 following positive Phase 3 clinical trial results.

How It Works

• Triple Receptor Activation: Combines GLP-1 and GIP (which regulate appetite and insulin secretion) with glucagon (which increases energy expenditure and fat burning).
• Enhanced Metabolism: Unlike medications that only suppress appetite, glucagon activation causes the body to burn more calories and breakdown fat tissue directly.

Clinical Trial Results & Timeline

• Weight Loss Efficacy: Phase 3 studies show average weight reductions of up to 24% to 28% (roughly 56 to 71 lbs) over extended treatment periods, matching levels previously seen only with bariatric surgery.
• Additional Benefits: Demonstrates significant improvements in blood sugar (HbA1c reduction in Type 2 diabetes), blood pressure, triglycerides, knee osteoarthritis pain, and sleep apnea.
• Approval Status: Not yet FDA-approved or commercially available by prescription; Eli Lilly expects to submit regulatory filings in Q1 2027.

Research References

Independent research information: [1, 2, 3]